SUIC and VisionRenu Partner to Advance AI Biotechnology and Precision Medicine

SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd., a Taiwan-based medical technology company, have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate on AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, announced on June 29, 2026, aims to position both companies in one of the world’s fastest-growing technology sectors.

Under the MOU, SUIC and VisionRenu will combine their strengths in medical technology innovation, commercialization, international business development, and access to U.S. capital markets. The collaboration is intended to accelerate VisionRenu’s global expansion while creating long-term value through strategic financing and business development. Both companies view this agreement as the first step toward building a long-term strategic partnership focused on innovation and sustainable growth.

Artificial Intelligence is rapidly reshaping the biotechnology industry, accelerating advances in gene editing, DNA synthesis, precision medicine, and digital biology. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and significantly shortens the development cycle for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through the Design-Build-Test-Learn platform, creating a new era of intelligent life science innovation.

Industry analysts expect AI-enabled biotechnology to become one of the world’s largest innovation markets over the coming decades, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials. Aligned with this global trend, SUIC’s strategic collaboration and proposed merger with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan’s Ministry of Health and Welfare, position the Company to expand into this rapidly growing sector.

VisionRenu is a Taiwan-based medical technology company focused on research, development, manufacturing, and commercialization of innovative medical devices for brain health and ophthalmic care. Its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, is approved by Taiwan’s TFDA for the treatment of depression. The company is also developing proprietary ophthalmic laser technologies. More information can be found at https://www.vision-renu.com/.

SUIC Worldwide Holdings Ltd. is a technology-enabled investment and business acceleration company focused on acquiring and developing innovative businesses with high-growth potential. Through strategic investments, mergers and acquisitions, and access to international capital markets, SUIC supports portfolio companies in expanding globally. Additional information is available at https://sinounitedco.com/.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is SUIC and VisionRenu Partner to Advance AI Biotechnology and Precision Medicine.

The post SUIC and VisionRenu Partner to Advance AI Biotechnology and Precision Medicine appeared first on citybuzz.